Apogee Therapeutics (APGE) traded higher as a new Street initiation turned sentiment more constructive, with a Buy rating and a $140 price target pointing to upside tied to its atopic dermatitis opportunity and nearer-term clinical catalysts. The initiation also emphasized that debate is now centered on the upcoming Phase 2 Part B dataset in atopic dermatitis expected in Q2 2026, keeping traders focused on the next incremental readout rather than near-term financial metrics. (ca.investing.com)

Apogee’s lead program, zumilokibart (APG777), is being developed as an anti-IL-13 antibody with the goal of combining strong efficacy with less frequent dosing. In late March, the company reported Phase 2 Part A 52-week data in moderate-to-severe atopic dermatitis showing durable maintenance metrics under every-3-month and every-6-month dosing schedules, which has kept the stock highly sensitive to follow-on trial updates. (investors.apogeetherapeutics.com)

The stock’s tone has also been supported by the company’s March financing actions, including an underwritten public offering announced March 24, 2026 and the closing announcement on March 26, 2026, which investors viewed as extending runway into multiple upcoming development milestones. With Apogee also approaching an early-to-mid May earnings window on many market calendars, positioning has been increasingly catalyst-driven. (globenewswire.com)

Near-term trading sensitivity is likely to remain tied to (1) any updates on the timing and design of the atopic dermatitis Phase 2 Part B readout expected in Q2 2026, and (2) additional clarity on Phase 3 initiation plans. Any confirmation of improved dosing convenience without sacrificing response durability could further reshape expectations for commercial differentiation in a competitive eczema market.